Dermatology Times 2024 In Review: Atopic Dermatitis

Dermavant Shares Positive Safety and Efficacy Data From Analysis of ADORING Program for Atopic Dermatitis

The additional efficacy data highlights tapinarof cream 1% and its impact on EASI, PP-NRS, ViGA-AD, and more.

Majority of Patients Treated With Roflumilast Cream 0.15% for AD Demonstrate Improvement in EASI Scores at 4 Weeks

The pooled analyses from Arcutis’ INTEGUMENT-1 and INTEGUMENT-2 studies were presented at the 2024 Winter Clinical Hawaii Dermatology Conference.

Psychological Stress Exacerbates Brain Activities in Female Patients With Atopic Dermatitis

Functional magnetic resonance imaging response was utilized to test motor, somatosensory association cortex, perception, and sensory integration processing in this study.

Mediating Factors in Secondhand Smoke and Atopic Dermatitis in Adolescents

Investigators highlighted the importance of considering household secondhand smoke exposure when evaluating adolescents with AD.

IGA, EASI, and Itch Endpoints Met in First In Human Phase 2 Trial of Zabalafin for Atopic Dermatitis

Interim data from the clinical trial was presented in a poster at the South Beach Symposium, with itch reduction demonstrating immediacy and long-term capability.

Atopic Dermatitis Itch May Be Caused by Microbes, Not Inflammation

Researchers have found Staphylococcus aureus may trigger itchiness in atopic dermatitis, opening the door to new treatment approaches in the future.

Zabalafin Hydrogel Significantly Improves Itch in Phase 2a Trial for AD

Alphyn’s first-in-class therapeutic is designed to treat the immune system component, and more specifically the bacterial component, of AD.

Tapinarof Cream 1% Efficacious in Adults and Children With Skin of Color Down to 2 Years With AD

New data was presented at the American Academy of Dermatology Annual Meeting in San Diego, California.

Amlitelimab Demonstrates Sustained Improvements in Atopic Dermatitis Signs and Symptoms

Late-breaking data demonstrating the sustained improvements was presented at the American Academy of Dermatology Annual Meeting.

Dupilumab Shows Superiority in Reducing Upper Respiratory Infections in Patients With AD

The risk of upper respiratory infection-related mortality was notably diminished in the study's dupilumab cohort.

Treatment With Tralokinumab Improved Epidermal Pathology, Reduced Systemic Markers In Type 2 Inflammation

Treatment also shifted the expression of key biomarkers in atopic dermatitis toward non-lesional levels, according to a study.

ASLAN Announces Positive Phase 2 Results of Eblasakimab in Dupilumab-Treated Patients With AD

Sixty percent of dupilumab-treated patients with AD treated with 400mg of eblasakimab weekly achieved EASI-90 after 16 weeks.

2 Years of Treatment With Dupilumab Led to Improvements In Symptoms of AD and Comorbid Anxiety, Depression

Following treatment, 17.5% and 13% of patients reported residual depressive and anxiety symptoms.

Substantial Disease Burden is Positively Correlated With a Greater Number of Atopic Dermatitis Lesion Locations

Patients with AD experienced significant impacts to disease severity, disease control, and quality of life regardless of lesion location count.

Abrocitinib Demonstrates High Efficacy In Itch-Dominant Atopic Dermatitis

Researchers found that abrocitinib demonstrated rapid, sustained, and deep improvements in several important domains of itch-dominant AD.

Efficacy of Dupilumab in Treating Atopic Hand and Foot Dermatitis

The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.

Analyzing the Impact of AD on Women’s Sexual Health

A study found that AD not only affects mental health and QoL, but women’s sexual health and gestational desires as well.

Lebrikizumab Maintains EASI 90 Responses up to 38 Weeks After Discontinuation

The post-hoc analysis evaluated the relationship between lebrikizumab serum concentration levels and sustained clinical response after lebrikizumab discontinuation.

The Role of Online Patient-Oriented Platforms in Dermatology

A study demonstrated the benefits and limitations of PatientsLikeMe for patients with atopic dermatitis and other skin conditions.

Preliminary Data on Therapy-Free Remission with Dupilumab for Pediatric Atopic Dermatitis

A significant proportion of pediatric patients with AD achieved and maintained clinical remission with dupilumab, according to a poster presented at the SPD's annual meeting.

Roflumilast Cream 0.15% for Atopic Dermatitis Now Commercially Available

Approved down to the age of 6, the treatment is covered by 2 pharmacy benefit manager contracts to provide timely coverage.

Turn Therapeutics Reports Significant IGA and Cytokine Inhibition, Advances to Plans for In-Human Trial

This article represents the first time the news has been shared with the public. Turn's Founder and CEO, Bradley Burnam, shares details.

Study Achieves International Consensus for Methotrexate Dosing in Patients With Atopic Dermatitis

Researchers said they hope this consensus guides prescribing decisions among clinicians and encourages development of a standard approach.

Positive Long-Term Results for Roflumilast Cream in Young Children

Results from the study highlight that the therapy improves AD symptoms over time, with 71.9% of participants achieving substantial improvement.

Defining Photosensitivity in Atopic Dermatitis

A study revealed a spectrum of photosensitivity in AD, with varying symptoms and sensitivities.

Lebrikizumab Shows Promise for Patients with Skin of Color and AD

The IL-13 inhibitor, FDA-approved for moderate to severe AD, reached all primary endpoints in the study focusing on patients with skin ofcolor.

AbbVie Presents New Data on Efficacy of Upadacitinib in Moderate to Severe Atopic Dermatitis, High-Impact Areas

An analysis from phase 3 studies shows Rinvoq's effectiveness for moderate to severe AD with head and neck involvement.

New LEVEL UP Period 2 Data Shows Patients Who Switched From Dupilumab to Upadacitinib Achieved Higher Treatment Targets in AD

Christopher Bunick, MD, PhD, presented the latest period 2 data at Fall Clinical 2024.

Final ECZTEND Study Results Confirm Long-Term Safety and Efficacy of Tralokinumab for Moderate-to-Severe Atopic Dermatitis

Adbry achieved EASI-75 in 92.9% and IGA 0/1 in 66.7% of AD patients, with a strong safety profile.

Rocatinlimab Improves SCORAD in Adults With Moderate to Severe AD

A poster presentation from Fall Clinical 2024 detailed the effect of rocatinlimab on SCORAD scores across baseline characteristic subgroups in adults with moderate to severe atopic dermatitis.

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD

The LIBERTY-AD PED-OLE study showed clinical remission for moderate to severe atopic dermatitis.

APP Insights Into AD Therapy: Systemics May Improve Patient Compliance

APPs found that patients on systemic therapies for AD experience fewer issues with adherence compared to those using topicals only.

FRONTIER-2 Study Evaluates Safety and Efficacy of Tozorakimab in Patients with AD

Patients with moderate to severe atopic dermatitis saw the most improvement after taking 600 mg of tozorakimab.

Apogee Announces Clinical Trial Advancements in APG777 for AD Treatment

Promising new data was released along with a timeline of upcoming studies evaluating potential combination therapies for atopic dermatitis.

Meta-Analysis Finds Upadacitinib to Be Most Effective for AD-Related Pruritus

Although all observed treatments showed efficacy, the 30 mg dosage of upadacitinib was most successful in relieving itch for atopic dermatitis patients.

Plasma Protein Analysis Identifies New Drug Targets for Atopic Dermatitis

A study using proteome-wide association techniques identified novel protein biomarkers for atopic dermatitis.

Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.